Neurosteroids for the pharmacotherapy of depression and other neuropsychiatric disorders: a review of clinical evidence
Year: 2026
Type: article
Abstract: Postpartum (perinatal) depression (PPD) and treatment-resistant depression are prevalent affective disorders characterized by poor responsiveness to conventional antidepressant therapy. The family of neurosteroids (neuroactive steroids) comprises a number of endogenous molecules produced in the central and peripheral nervous systems, as well as their synthetic analogues, which are being investigated as promising therapeutic candidates. The primary mechanism of action of neurosteroids is based on the regulation of neuronal excitability through allosteric modulation of synaptic and extrasynaptic γ-aminobutyric acid receptors, predominantly the A subtype. Weak positive allosteric modulation of N-methyl-D-aspartate glutamate receptors and agonism at σ1-receptors further enhance the antidepressant effect and also account for the procognitive and neuroprotective properties observed in some neurosteroids. One of the most important advantages of neurosteroids as antidepressants is their rapid onset of action, which may be observed after the first administration. Zuranolone, available as oral capsules, has been approved in the United States and the European Union for the treatment of PPD in patients aged 18 years and older. In a number of clinical trials, zuranolone has demonstrated efficacy in major depressive disorder, bipolar disorder, insomnia, tremor, and other symptoms of Parkinson’s disease. Clinical studies of other compounds in this class, including brexanolone caprilcerbate, 3β-methoxypregnenolone, fasedienol, itruvone, C, and PH15, are currently ongoing. Ganaxolone is approved in several countries for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Its potential use in the treatment of focal and generalized treatment-resistant epilepsy, as well as for the management of status epilepticus, is currently being evaluated in clinical trials. In summary, neurosteroids represent a promising new class of pharmacologically active compounds that are of considerable interest as therapeutic candidates with a broad range of potential clinical applications, including affective and anxiety disorders, sleep disturbances, neurodegenerative diseases, and various forms of epilepsy.
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7236106554
